Literature DB >> 34003218

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

Karina W Davidson1, Michael J Barry2, Carol M Mangione3, Michael Cabana4, Aaron B Caughey5, Esa M Davis6, Katrina E Donahue7, Chyke A Doubeni8, Alex H Krist9,10, Martha Kubik11, Li Li12, Gbenga Ogedegbe13, Douglas K Owens14, Lori Pbert15, Michael Silverstein16, James Stevermer17, Chien-Wen Tseng18,19, John B Wong20.   

Abstract

Importance: Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening. Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies. Population: Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]). Evidence Assessment: The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit. Recommendation: The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).

Entities:  

Mesh:

Year:  2021        PMID: 34003218     DOI: 10.1001/jama.2021.6238

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  123 in total

1.  Financial Incentives to Improve Colorectal Cancer Screening-Time to Cut Our Losses.

Authors:  Rachel B Issaka; Jason A Dominitz
Journal:  JAMA Netw Open       Date:  2021-08-02

2.  Factors associated with colorectal cancer screening intent and uptake among adult Non-Hispanic Black men.

Authors:  Charles R Rogers; Roger Figueroa; Ellen Brooks; Ethan M Petersen; Carson D Kennedy; Darrell M Gray Ii; Michael Sapienza; Man Hung
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

3.  Review of Cancer-Specific Quality Measures Promoting the Avoidance of Low-Value Care.

Authors:  Brandon L Ellsworth; Allan K Metz; Nicole M Mott; Ruby Kazemi; Michael Stover; Tasha Hughes; Lesly A Dossett
Journal:  Ann Surg Oncol       Date:  2022-02-06       Impact factor: 5.344

4.  Primary Care Concerns for the Aging Population With HIV.

Authors:  Steve C Johnson
Journal:  Top Antivir Med       Date:  2021 Oct-Nov

Review 5.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

6.  Is it time to lower the colorectal cancer screening age in average-risk adults in Singapore?

Authors:  Tiing Leong Ang; Khay Guan Yeoh
Journal:  Singapore Med J       Date:  2021-12       Impact factor: 1.858

Review 7.  Healthcare Disparities and Colorectal Cancer.

Authors:  Robert H Hollis; Daniel I Chu
Journal:  Surg Oncol Clin N Am       Date:  2022-03-08       Impact factor: 3.495

8.  Increasing Incidence Rates of Colorectal Cancer at Ages 50-54 Years.

Authors:  Timothy A Zaki; Amit G Singal; Folasade P May; Caitlin C Murphy
Journal:  Gastroenterology       Date:  2021-10-29       Impact factor: 22.682

9.  Colorectal Cancer Screening Starting at Age 45 Years-Ensuring Benefits Are Realized by All.

Authors:  Shivan J Mehta; Arden M Morris; Sonia S Kupfer
Journal:  JAMA Netw Open       Date:  2021-05-03

10.  Itaconate and leptin affecting PPARγ in M2 macrophages: A potential link to early-onset colorectal cancer.

Authors:  Katharina M Scheurlen; Dylan L Snook; Mary N Walter; Cheyenne N Cook; Casey R Fiechter; Jianmin Pan; Robert J Beal; Susan Galandiuk
Journal:  Surgery       Date:  2021-12-06       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.